Sarepta Therapeutics, Inc. (SRPT)
| Market Cap | 1.72B -8.9% |
| Revenue (ttm) | 1.96B -18.9% |
| Net Income | -114.62M |
| EPS | -1.09 |
| Shares Out | 107.24M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,209,659 |
| Open | 16.44 |
| Previous Close | 16.68 |
| Day's Range | 15.99 - 16.63 |
| 52-Week Range | 14.68 - 24.68 |
| Beta | 0.45 |
| Analysts | Hold |
| Price Target | 21.77 (+35.98%) |
| Earnings Date | Nov 5, 2026 |
About SRPT
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 24 analysts, the average rating for SRPT stock is "Hold." The 12-month stock price target is $21.77, which is an increase of 35.98% from the latest price.
News
Sarepta upgraded to Hold from Sell at Deutsche Bank
Deutsche Bank analyst David Hoang upgraded Sarepta (SRPT) to Hold from Sell with an $18 price target
5-star Deutsche upgrades Sarepta to Hold on improving fundamentals
Deutsche Bank upgraded Sarepta (SRPT) to Hold from Sell with a price target of $18, up from $14. Following the Q3 report, the firm is more confident that a large…
PepGen data offer ‘encouraging’ readthrough for Sarepta, says RBC Capital
PepGen’s (PEPG) DM1 data offer encouraging readthroughs for Sarepta’s (SRPT) upcoming DM1 and FSHD readouts, with early functional signals potentially supportive, but variable biomarker-function relat...
Sarepta Therapeutics Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference
Commercial exon-skipping therapies are positioned to retain stable patients amid potential competition, while ELEVIDYS demand is being assessed against a clean baseline. DM1 and FSHD data and Huntington’s proof of biology could advance three programs toward pivotal development or accelerated approval.
Sarepta price target lowered to $18 from $20 at Baird
Baird lowered the firm’s price target on Sarepta (SRPT) to $18 from $20 and keeps a Neutral rating on the shares. The firm updated its model following Q3 results with…
Sarepta sees Q4 net product revenue in line with Q3
Sarepta (SRPT) states: “Company expects ELEVIDYS net product revenue in the fourth quarter to trend in line with the third quarter, consistent with previous guidance and subject to normal variability…
Sarepta reports Q3 EPS 13c, consensus 36c
Reports Q3 revenue $381.4M, consensus $350.1M. “After my first 90 days at Sarepta (SRPT), I believe the fundamental strengths that attracted me to the company remain firmly intact: a durable…
Sarepta Therapeutics Earnings Call Transcript: Q3 2026
Q3 product revenue was $324M, while non-GAAP operating profit reached $23M and cash and investments approached $1B. FY2026 revenue guidance rose to $1.25B-$1.3B as ELEVIDYS stabilized and the PMO franchise remained strong; DM1 and FSHD data are imminent.
Sarepta Therapeutics Quarterly report: Q3 2026
Sarepta Therapeutics has published its Q3 2026 quarterly earnings report on November 5, 2026.
Sarepta Therapeutics Earnings release: Q3 2026
Sarepta Therapeutics released its Q3 2026 earnings on November 5, 2026, summarizing the period's financial results.
Sarepta Therapeutics Slides: Q3 2026
Sarepta Therapeutics has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 5, 2026.
Sarepta Therapeutics Announces Third Quarter 2026 Financial Results and Recent Corporate Developments
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the third quarter of 2026....
Sarepta Therapeutics to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in the ...
Sarepta Therapeutics to Announce Third Quarter 2026 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report third quarter 2026 financial results after the Nasd...
Sarepta presents new preclinical data at 22nd Meeting of OTS on SRP-1003
Sarepta (SRPT) Therapeutics presented new preclinical data at the 22nd Annual Meeting of the Oligonucleotide Therapeutics Society, OTS, demonstrating that SRP-1003, the company’s investigational small...
Sarepta Therapeutics Presents New Preclinical Data Demonstrating Robust Knockdown of Pathogenic DMPK RNA in the Nucleus with SRP-1003 in DM1 at 2026 Oligonucleotide Therapeutics Society Annual Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today presented new preclinical data at the 22nd Annual Meeting...
Sarepta price target lowered to $17 from $19 at RBC Capital
RBC Capital lowered the firm’s price target on Sarepta (SRPT) to $17 from $19 and keeps a Sector Perform rating on the shares as part of a broader research note…
Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPT
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced...
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on Sept. 30, 2026 that were previously ap...
Sarepta presents new data on ELEVIDYS in DMD at WMS Congress
Sarepta (SRPT) Therapeutics presented new data at the 31st Annual Congress of the World Muscle Society) that provide evidence of clinically meaningful functional benefit of ELEVIDYS in older ambulator...
Sarepta Therapeutics Presents New Data at 2026 World Muscle Society Annual Congress Demonstrating Safety and Clinically Meaningful Functional Benefit of ELEVIDYS (delandistrogene moxeparvovec) in Older Ambulatory Patients with Duchenne
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today presented new data at the 31st Annual Congress of the Wor...
Sarepta price target lowered to $20 from $23 at JPMorgan
JPMorgan lowered the firm’s price target on Sarepta (SRPT) to $20 from $23 and keeps a Neutral rating on the shares. The firm updated the company’s model. Published first on…
Sarepta Therapeutics Announces Presentations at 2026 World Muscle Society Annual Congress
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will present new data from its portfolio of treatments for Duch...
Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 27th Annual Neuromuscular Study Group Scientific Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will present new data at the 27th Annual Neuromuscular Study Gr...
Sarepta Therapeutics Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
The discussion highlighted stabilization and gradual growth in commercial products, strong early clinical data for FSHD and DM1 programs, and a focus on maximizing gene knockdown. Multiple ascending dose data for both programs are expected in the second half of the year, with further expansion and competition anticipated.